Please assess the completion status of the following clinical trial:

Trial Title: Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients are to be greater than 40 kg body weight.~* Patients must have adequate veins to provide intravenous access.~* Women who are not pregnant, lactating, or of childbearing potential. Lack of childbearing potential was defined as:~  * Being post-menopausal~ * Being surgically sterile~ * Practicing contraception~* Patients with childbearing potential had to have a negative serum human chorionic gonadotropin (HCG) upon entrance into the study.~* Patients must be willing to adhere to the protocol, and sign an Informed Patient Consent Form prior to entry into the study.~* Patients must not be on any other investigational device/drug treatment.~* Patients with the diagnosis of mycosis fungoides (MF) including a skin biopsy consistent with MF (atypical epidermotrophic or folliculocentric T-cells).~* Appropriate staging as IA, IB or IIA : T1 or T2 (patches or plaques) with measurable lesions.~  * IA patients must show evidence of a minor blood abnormality by morphology or laboratory assessment.~ * For IIA patients - clinically significant nodes (1.5 cm) must have lymph node biopsy showing dermatopathic nodes or no involvement.~* Patients must be willing and able to discontinue concomitant medications for MF.~* Patients currently taking the following drugs must discontinue medication prior to enrollment in the trial:~  * Psoralens and ultraviolet A (PUVA) or ultraviolet B (UVB) therapy - 4 weeks~ * Topical nitrogen mustard or other topical chemotherapy - 4 weeks~ * Bexarotene capsules or other systemic biologic agent - 3 weeks washout~ * High dose topical steroids, topical retinoids or immunotherapy - 2 week washout with 1% topical hydrocortisone~ * Oral steroids above 10 mg - 30 day washout, unless patient has Addison's disease or adrenal insufficiency~* Patients must be refractory to at least one of the standard therapies used to treat Stage IA, IB or IIA CTCL such as oral steroids, high-dose topical steroids, mechlorethamine (HN2), bexarotene, PUVA therapy, electron beam radiation, biological response or oral methotrexate.~* Patients must abstain from therapeutic sunbathing, tanning beds, etc. for the duration of the study.~Exclusion Criteria:~* Patients who have MF (T3 cutaneous tumors or T4 exfoliative erythroderma) Stage IIB - IVB, ie. no pathological node or visceral involvement.~* Patients who are unable to tolerate extracorporeal volume loss (e.g., severe cardiac disease or severe anemia or weight \< 40 kg).~* Patients with recent (within three months) deterioration of renal function who have a serum creatinine level greater than 3.0 mg/dL.~* Patients with lipemic plasma \> 500 ng/dL or uncontrolled diabetes.~* Patients with a history of liver damage (2.5 x normal ALT, AST) or porphyria.~* Patients with positive tests for HIV antibody, hepatitis C virus (HCV) antibody or hepatitis B surface antigen.~* Patients on oral prednisone therapy or full body or high potency topical steroids.~* Women who are pregnant or nursing a child.~* Patients with severe emotional, behavioral or psychiatric problems that, in the opinion of the investigator, would result in poor compliance with the treatment regimen.~* Patients who exhibit idiosyncratic or hypersensitivity reactions to 8-methoxypsoralen compounds, heparin, or citrate.~* Patients with previous exposure to photopheresis therapy.~* Patients who use tanning beds or are receiving phototherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DRUG+ECP (Type: EXPERIMENTAL): UVVADEX +ECP will be administered to patients with CTCL.Duration of Treatment: The study will consist of 2 treatment periods, a 6-month initial period and a 6-month follow-up period where photopheresis therapy may continue.

Based on this trial design, predict the completion outcome and termination type (if applicable).